Fiche publication
Date publication
août 2026
Journal
Annals of clinical and translational neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Moukhine A, Rollot F, Casey R, Collongues N, Vukusic S, Mathey G, Dubessy AL, Ciron J, De Seze J, Ruet A, Labauge P, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Laplaud DA, Berger E, Thouvenot E, Pelletier J, Al Khedr A, Casez O, Bourre B, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Rivière MS, Hankiewicz K, Santos AD, Pottier C, Manchon E, Aboab J, Tchikviladze M, David T, Edan G, Le Page E, Michel L, Kerbrat A,
Lien Pubmed
Résumé
To determine whether discontinuing anti-CD20 therapy in people with relapsing-onset MS aged over 50 is associated with an increased risk of relapse, inflammatory activity, confirmed disability accrual, and serious infection compared with continuing therapy.
Mots clés
anti‐CD20, discontinuation, multiple sclerosis
Référence
Ann Clin Transl Neurol. 2026 08 13;:
